254 related articles for article (PubMed ID: 22198767)
41. Autoantibodies from patients with coeliac disease recognize distinct functional domains of the autoantigen tissue transglutaminase.
Seissler J; Wohlrab U; Wuensche C; Scherbaum WA; Boehm BO
Clin Exp Immunol; 2001 Aug; 125(2):216-21. PubMed ID: 11529912
[TBL] [Abstract][Full Text] [Related]
42. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope.
Anderson RP; Degano P; Godkin AJ; Jewell DP; Hill AV
Nat Med; 2000 Mar; 6(3):337-42. PubMed ID: 10700238
[TBL] [Abstract][Full Text] [Related]
43. Synthetic peptides reproducing tissue transglutaminase-gliadin complex neo-epitopes as probes for antibody detection in celiac disease patients' sera.
Di Pisa M; Pascarella S; Scrima M; Sabatino G; Real-Fernández F; Chelli M; Renzi D; Calabrò A; D'Ursi AM; Papini AM; Rovero P
J Med Chem; 2015 Feb; 58(3):1390-9. PubMed ID: 25588142
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive Detection of Isopeptides between Human Tissue Transglutaminase and Gluten Peptides.
Lexhaller B; Ludwig C; Scherf KA
Nutrients; 2019 Sep; 11(10):. PubMed ID: 31547042
[TBL] [Abstract][Full Text] [Related]
45. T-cell and B-cell immunity in celiac disease.
du Pré MF; Sollid LM
Best Pract Res Clin Gastroenterol; 2015 Jun; 29(3):413-23. PubMed ID: 26060106
[TBL] [Abstract][Full Text] [Related]
46. Involvement of cell surface TG2 in the aggregation of K562 cells triggered by gluten.
Feriotto G; Calza R; Bergamini CM; Griffin M; Wang Z; Beninati S; Ferretti V; Marzola E; Guerrini R; Pagnoni A; Cavazzini A; Casciano F; Mischiati C
Amino Acids; 2017 Mar; 49(3):551-565. PubMed ID: 27699491
[TBL] [Abstract][Full Text] [Related]
47. Intestinal anti-tissue transglutaminase antibodies in potential coeliac disease.
Tosco A; Aitoro R; Auricchio R; Ponticelli D; Miele E; Paparo F; Greco L; Troncone R; Maglio M
Clin Exp Immunol; 2013 Jan; 171(1):69-75. PubMed ID: 23199325
[TBL] [Abstract][Full Text] [Related]
48. Deamidated gliadin peptides as targets for celiac disease-specific antibodies.
Mothes T
Adv Clin Chem; 2007; 44():35-63. PubMed ID: 17682339
[TBL] [Abstract][Full Text] [Related]
49. High-Throughput Single-Cell Analysis of B Cell Receptor Usage among Autoantigen-Specific Plasma Cells in Celiac Disease.
Roy B; Neumann RS; Snir O; Iversen R; Sandve GK; Lundin KEA; Sollid LM
J Immunol; 2017 Jul; 199(2):782-791. PubMed ID: 28600290
[TBL] [Abstract][Full Text] [Related]
50. Deamidation of gliadin peptides in lamina propria: implications for celiac disease.
Skovbjerg H; Anthonsen D; Knudsen E; Sjöström H
Dig Dis Sci; 2008 Nov; 53(11):2917-24. PubMed ID: 18679797
[TBL] [Abstract][Full Text] [Related]
51. Selective activation of naïve B cells with unique epitope specificity shapes autoantibody formation in celiac disease.
Das S; Stamnaes J; Høydahl LS; Skagen C; Lundin KEA; Jahnsen J; Sollid LM; Iversen R
J Autoimmun; 2024 Jun; 146():103241. PubMed ID: 38754235
[TBL] [Abstract][Full Text] [Related]
52. Autoantibodies and CD: past and future of celiac antibody testing.
Korponay-Szabó IR
J Pediatr Gastroenterol Nutr; 2014 Jul; 59 Suppl 1():S11-3. PubMed ID: 24979192
[TBL] [Abstract][Full Text] [Related]
53. Tissue transglutaminase and celiac disease.
Esposito C; Caputo I; Auricchio S; Troncone R
Prog Exp Tumor Res; 2005; 38():158-73. PubMed ID: 15746535
[No Abstract] [Full Text] [Related]
54. The propensity for deamidation and transamidation of peptides by transglutaminase 2 is dependent on substrate affinity and reaction conditions.
Stamnaes J; Fleckenstein B; Sollid LM
Biochim Biophys Acta; 2008 Nov; 1784(11):1804-11. PubMed ID: 18793760
[TBL] [Abstract][Full Text] [Related]
55. Transglutaminase 2 in celiac disease: minireview article.
Caputo I; D'Amato A; Troncone R; Auricchio S; Esposito C
Amino Acids; 2004 Jul; 26(4):381-6. PubMed ID: 15290344
[TBL] [Abstract][Full Text] [Related]
56. Autoantibodies from patients with celiac disease inhibit transglutaminase 2 binding to heparin/heparan sulfate and interfere with intestinal epithelial cell adhesion.
Teesalu K; Panarina M; Uibo O; Uibo R; Utt M
Amino Acids; 2012 Feb; 42(2-3):1055-64. PubMed ID: 21847613
[TBL] [Abstract][Full Text] [Related]
57. Immunoreactivity of antibodies against transglutaminase-deamidated gliadins in adult celiac disease.
Falini ML; Elli L; Caramanico R; Bardella MT; Terrani C; Roncoroni L; Doneda L; Forlani F
Dig Dis Sci; 2008 Oct; 53(10):2697-701. PubMed ID: 18306039
[TBL] [Abstract][Full Text] [Related]
58. Celiac anti-type 2 transglutaminase antibodies induce phosphoproteome modification in intestinal epithelial Caco-2 cells.
Paolella G; Caputo I; Marabotti A; Lepretti M; Salzano AM; Scaloni A; Vitale M; Zambrano N; Sblattero D; Esposito C
PLoS One; 2013; 8(12):e84403. PubMed ID: 24391952
[TBL] [Abstract][Full Text] [Related]
59. Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease.
Büchold C; Hils M; Gerlach U; Weber J; Pelzer C; Heil A; Aeschlimann D; Pasternack R
Cells; 2022 May; 11(10):. PubMed ID: 35626704
[TBL] [Abstract][Full Text] [Related]
60. Transglutaminase 2 is expressed and active on the surface of human monocyte-derived dendritic cells and macrophages.
Hodrea J; Demény MA; Majai G; Sarang Z; Korponay-Szabó IR; Fésüs L
Immunol Lett; 2010 May; 130(1-2):74-81. PubMed ID: 20005901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
